Oncternal TherapeuticsONCT
About: Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Employees: 27
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
5.18% less ownership
Funds ownership: 16.83% [Q2] → 11.65% (-5.18%) [Q3]
19% less funds holding
Funds holding: 26 [Q2] → 21 (-5) [Q3]
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
88% less capital invested
Capital invested by funds: $3.79M [Q2] → $455K (-$3.33M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Northland Capital Markets Carl Byrnes 75% 1-year accuracy 3 / 4 met price target | 75%upside $2 | Market Perform Downgraded | 12 Sept 2024 |
